secwatch / observer
8-K filed July 11, 2023, 7:59 PM ET ticker BCRX CIK 0000882796
leadership confidence high sentiment neutral materiality 0.40

BioCryst principal accounting officer resigns; CFO to serve as interim

BIOCRYST PHARMACEUTICALS INC

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Anthony Doyle

Interim Principal Accounting Officer
BCRX · BIOCRYST PHARMACEUTICALS INC
Effective
2023-07-10
Filed
July 11, 2023, 7:59 PM ET
On July 10, 2023, the Board of Directors of the Company appointed Anthony Doyle, the Company’s Chief Financial Officer, to serve as interim Principal Accounting Officer, effective as of the same date.
Departed

Michael L. Jones

Principal Accounting Officer
BCRX · BIOCRYST PHARMACEUTICALS INC
Effective
2023-07-07
Successor
Anthony Doyle
Filed
July 11, 2023, 7:59 PM ET
On July 7, 2023, Michael L. Jones, Executive Director, Finance and Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”), informed the Company of his intention to resign from the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anthony Doyle was appointed as Interim Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.

Action
appointed
Role
Interim Principal Accounting Officer
Exact text from the filing
On July 10, 2023, the Board of Directors of the Company appointed Anthony Doyle, the Company’s Chief Financial Officer, to serve as interim Principal Accounting Officer, effective as of the same date.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Michael L. Jones resigned as Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.

Action
resigned
Role
Principal Accounting Officer
Exact text from the filing
On July 7, 2023, Michael L. Jones, Executive Director, Finance and Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”), informed the Company of his intention to resign from the Company.
View on SEC.gov

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR
accession 0001171843-23-004444
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.